PFEB logo

Pfizer DB:PFEB Stock Report

Last Price

€8.70

Market Cap

€143.4b

7D

-0.6%

1Y

-31.5%

Updated

25 Mar, 2024

Data

Company Financials +

PFEB Stock Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.

PFEB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance1/6
Financial Health1/6
Dividends4/6

Pfizer Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pfizer
Historical stock prices
Current Share PriceUS$8.70
52 Week HighUS$13.30
52 Week LowUS$8.10
Beta0.56
1 Month Change-0.57%
3 Month Change-2.79%
1 Year Change-31.50%
3 Year Changen/a
5 Year Changen/a
Change since IPO-46.18%

Recent News & Updates

Recent updates

Shareholder Returns

PFEBDE PharmaceuticalsDE Market
7D-0.6%3.0%1.3%
1Y-31.5%-25.6%6.4%

Return vs Industry: PFEB underperformed the German Pharmaceuticals industry which returned -25.6% over the past year.

Return vs Market: PFEB underperformed the German Market which returned 6.4% over the past year.

Price Volatility

Is PFEB's price volatile compared to industry and market?
PFEB volatility
PFEB Average Weekly Movement4.2%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: PFEB has not had significant price volatility in the past 3 months.

Volatility Over Time: PFEB's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
184988,000Albert Bourlahttps://www.pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands.

Pfizer Inc. Fundamentals Summary

How do Pfizer's earnings and revenue compare to its market cap?
PFEB fundamental statistics
Market cap€143.37b
Earnings (TTM)€1.97b
Revenue (TTM)€54.13b

72.6x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PFEB income statement (TTM)
RevenueUS$58.50b
Cost of RevenueUS$23.99b
Gross ProfitUS$34.51b
Other ExpensesUS$32.37b
EarningsUS$2.13b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 01, 2024

Earnings per share (EPS)0.38
Gross Margin58.99%
Net Profit Margin3.65%
Debt/Equity Ratio80.8%

How did PFEB perform over the long term?

See historical performance and comparison

Dividends

6.1%

Current Dividend Yield

434%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.